Alphaform AG / Key word(s): Capital Increase
15.09.2014 20:32
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad-hoc disclosure Alphaform AG
Alphaform AG - Resolution on capital increase from authorised capital -
purchase price for new shares at EUR 2.75
Feldkirchen, near Munich, 15 September 2014 - The Management Board of
Alphaform AG today resolved with the Supervisory Board's consent to
increase the company's share capital through partial utilisation of the
company's Authorised Capital in accordance with Article 5 (2) of the
company's articles of association by up to EUR 1,800,000.00 from EUR
5,850,000.00 at present to up to EUR 7,650,000.00 by issuing up to
1,800,000 new no-par value bearer shares, each with a pro rata share of the
share capital of EUR 1.00. The new shares are entitled to dividends as of 1
January 2014. A subscription right is granted to the shareholders.
The new shares are to be subscribed to by Close Brothers Seydler Bank AG,
Frankfurt am Main, and acquired with the obligation to offer them to
shareholders of Alphaform AG at a ratio of 13:4 with a purchase price of
EUR 2.75 per share. The three major shareholders LHUM Vermöghensverwaltungs
GmbH, Falk Strascheg Holding GmbH und Renate Strascheg Holding GmbH have
pledged to the company to exercise their subscription rights entirely. At
full placement, the company shall receive issue proceeds of up to EUR
4,950,000.00. The shareholders' subscription period is expected to begin on
18 September 2014 and conclude at the end of 6 October 2014.Unsubscribed
shares shall be offered to institutional and strategic investors at a fixed
purchase price as part of a private placement.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About Alphaform
Alphaform AG, based in Feldkirchen near Munich was founded in 1996. The
company belongs to the European market leaders in the production of complex
components means additive manufacturing, which are often grouped together
under the term '3D printing'. An important mainstay of the segment 3D
Printing an Additive Manufacturing ist the production of series close
prototypes, particularly for the automotive and capital goods industries.
The Medical Devision of Alphaform has al leading position throughout Europe
in manufacturing and processing orthopaedic implants and instruments. The
shares of alphaform are listed in the Prime Standard Segment of the
Frankfurt Stock Exchange (FWB) under the abbreviation ATF.
The core competence of Alphaform lies in its extensive application know how
for processes and materials for additive production of complex prototypes,
tools, individual components and small series made of plastic and metal.
The company's activity is focused on the orthopaedic and medical
technology, automotive, aviation and aerospace industries. The subsidiaries
of Alphaform are located in Germany, Finland, Sweden and the UK.
Contact:
Dr. Hanns-Dieter Aberle, CEO
ALPHAFORM AG
KapellenstraÃe 10
85622 Feldkirchen
Tel.: +49 89 905002 35
Fax: +49 89 905002 1035
e-mail: hdaberle@alphaform.de
Internet: www.alphaform.de
Disclaimer
This press release/ad-hoc disclosure is not an offer document and does not
constitute an offer of shares of Alphaform AG ('Company') nor an invitation
to an offer to buy or subscribe for shares or securities of the Company but
is provided for information only. This press release/ad-hoc disclosure may
contain forward-looking statements that are subject to risks and
uncertainties, including those pertaining to the anticipated benefits to be
realized from the proposals described herein. Forward-looking statements
may include, in particular, statements about future events, future
financial performance, plans, strategies, expectations, prospects,
competitive environment, regulation and supply and demand. The Company has
based these forward-looking statements on its views and assumptions with
respect to future events and financial performance. Actual financial
performance could differ materially from that projected in the
forward-looking statements due to the inherent uncertainty of estimates,
forecasts and projections, and financial performance may be better or worse
than anticipated. Given these uncertainties, persons should not put undue
reliance on any forward-looking statements. The information contained in
this presentation is subject to change without notice and the Company does
not undertake any duty to update the forward-looking statements, and the
estimates and assumptions associated with them, except to the extent
required by applicable laws and regulations.
Important notice to persons in the United States of America
All information in this press release/ad-hoc disclosure is being made
available in the United States of America only to persons believed by the
Company to be capable of understanding and evaluating the risks of a
transaction. No shares or other securities of the Company have been
registered or otherwise qualify for a public sale or resale under federal
or state laws in the United States of America. Each recipient of
information doing business in or organized under any federal or state laws
in the United States of America or in areas subject to its jurisdiction
represents that it is an 'accredited investor' as defined by Rule 501 or
Regulation D under the Securities Act of 1993 ('the Act') and acknowledges
that none of the shares in the Company will be registered under the Act and
cannot be resold in the absence of such registration or the availability of
an exemption there from. The shares in the Company have not been approved
or disapproved by the United States Securities and Exchange Commission, any
state securities commission or other regulatory authority, nor have any of
these authorities passed judgment upon or endorsed the merits of an
investment in the shares of the Company or the accuracy or adequacy of this
presentation. Any representation to the contrary is a criminal offence.
Important notice to persons in the United Kingdom
All information in this press release/ad-hoc disclosure is being made
available to the recipients on the basis that they are persons covered by
Article 11(3) of the Financial Services Act 1986 (Investment
Advertisements) (Exemptions) Order 1996. By accepting this document the
recipient warrants and represents that he or it is such a person.
15.09.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Alphaform AG
KapellenstraÃe 10
85622 Feldkirchen
Germany
Phone: +49 (0)89 905002 - 0
Fax: +49 (0)89 905002 - 90
E-mail: ir@alphaform.de
Internet: www.alphaform.de
ISIN: DE0005487953
WKN: 548795
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Alphaform AG: Alphaform AG - Resolution on capital increase from authorised capital - purchase price for new shares at EUR 2.75
| Source: EQS Group AG